# AMG 319 in HPV Positive and Negative HNSCC

> **NCT02540928** · PHASE2 · TERMINATED · sponsor: **Cancer Research UK** · enrollment: 35 (actual)

## Conditions studied

- Human Papillomavirus (HPV)
- Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx

## Interventions

- **DRUG:** AMG 319 hydrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02540928
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-05-03
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Safety Reasons
- **Last updated:** 2018-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02540928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02540928, "AMG 319 in HPV Positive and Negative HNSCC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02540928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*